Table 2.
Association between KYNU mRNA expression and clinicopathologic characteristics in METABRIC cohort.
| Expression |
P-value | |||
|---|---|---|---|---|
| Total (n = 1904) | KYNU high (n = 952) | KYNU low (n = 952) | ||
| Age (years) | ||||
| ≥55 | 952 (50.0%) | 535 (56.2%) | 417 (43.8%) | <0.001 |
| <55 | 952 (50.0%) | 417 (43.8%) | 535 (56.2%) | |
| Tumor size | ||||
| ≥2 cm | 592 (31.1%) | 298 (31.3%) | 294 (30.9%) | 0.857 |
| <2 cm | 1292 (67.9%) | 643 (67.5%) | 649 (68.2%) | |
| Unknown | 20 (1.1%) | 11 (1.2%) | 9 (0.9%) | |
| AJCC stage | ||||
| 0 | 4 (0.2%) | 3 (0.3%) | 1 (0.1%) | 0.004 |
| I | 475 (24.9%) | 217 (22.8%) | 258 (27.1%) | |
| II | 800 (42.0%) | 420 (44.1%) | 380 (39.9%) | |
| III | 115 (6.0%) | 71 (7.5%) | 44 (4.6%) | |
| IV | 9 (0.5%) | 2 (0.2%) | 7 (0.7%) | |
| Unknown | 501 (26.3%) | 239 (25.1%) | 262 (27.5%) | |
| Tumor Grade | ||||
| I | 165 (8.7%) | 55 (5.8%) | 110 (11.6%) | <0.001 |
| II | 740 (38.9%) | 279 (29.3%) | 461 (48.4%) | |
| III | 927 (48.7%) | 588 (61.8%) | 339 (35.6%) | |
| Unknown | 72 (3.8%) | 30 (3.2%) | 42 (4.4%) | |
| ER status | ||||
| Negative | 445 (23.4%) | 359 (37.7%) | 86 (9.0%) | <0.001 |
| Positive | 1459 (76.6%) | 593 (62.3%) | 866 (91.0%) | |
| PR status | ||||
| Negative | 895 (47.0%) | 558 (58.6%) | 337 (35.4%) | <0.001 |
| Positive | 1009 (53.0%) | 394 (41.4%) | 615 (64.6%) | |
| HER2 status | ||||
| Negative | 1668 (87.6%) | 771 (81.0%) | 897 (94.2%) | <0.001 |
| Positive | 236 (12.4%) | 181 (19.0%) | 55 (5.8%) | |